Acute hemorrhagic conjunctivitis

Summary

Acute hemorrhagic conjunctivitis (MONDO:0005634) is a disease. A subtype of acute conjunctivitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute hemorrhagic conjunctivitis
Mondo ID	MONDO:0005634
EFO	EFO:0007131
MeSH	D003232
DOID	DOID:11227
NCIT	C34505
SNOMED CT	398264003
UMLS	C0009765
MedGen	1094
Is cancer (heuristic)	no

Also known as: epidemic hemorrhagic conjunctivitis

Disease family

This is a subtype of acute conjunctivitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › conjunctival disorder › conjunctivitis › acute conjunctivitis › acute hemorrhagic conjunctivitis

Related subtypes (5): pseudomembranous conjunctivitis, serous conjunctivitis except viral, Angelucci syndrome, acute contagious conjunctivitis, conjunctival folliculosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.